History

All monetary figures in Indian Rupees (₹), expressed in crore (₹ Cr; 1 crore = ₹10 million). Ratios and percentages are unchanged between this file and its USD sibling.

1. The Narrative Arc

India's largest standalone health insurer has spent eight years building scale, had that scale nearly destroyed by COVID, and is now — tentatively — demonstrating the underwriting discipline the original investment thesis assumed.

The company's history breaks into four acts. Pre-COVID (FY2018–FY2020), GWP grew at 28% CAGR from ₹4,161 Cr to ₹6,865 Cr with consistent profitability. The pandemic (FY2021–FY2022) produced combined ratios of 122% and 118% and back-to-back losses totaling ₹2,127 Cr — proving the company's high-frequency retail model had no structural defense against a systemic claims event. The FHO-led recovery (FY2023–FY2024) reached 97.3% combined ratio in FY2024, and management announced ₹30,000 Cr GWP by FY2028.

Then FY2025 happened: loss ratio 70.3% (400bps above target), combined ratio 101.1%, a cyber attack, and an analyst confrontation at Q4 earnings that forced genuine portfolio repositioning. FY2026 is the recovery: ₹20,369 Cr GWP (+16% on statutory 1/n basis; +21% on N-basis), combined ratio 98.8%, first underwriting profit (₹206 Cr) since FY2024, and a Q4 loss ratio of 65.2% — the best single quarter in company history.

The PAT chart captures the two COVID loss years (FY2021: −₹1,086 Cr, FY2022: −₹1,041 Cr), the recovery (FY2023: ₹619 Cr, FY2024: ₹845 Cr), the FY2025 regression despite higher GWP (₹646 Cr), and FY2026 normalization (₹911 Cr actual; ₹1,222 Cr on normalized 8% investment yield basis).

---

2. What Management Emphasized, Changed, and Stopped

Management's vocabulary shifted four times across eight earnings calls — often faster than the underlying business changed.

What management stopped doing (permanently):

• Group employer-employee business — fully exited by Q2 FY2026; described as "unprofitable, not aligned with retail focus"
• "GWP doubling" language — explicitly walked back at Q4 FY2025; FY2028 target restated as "₹30,000 Cr may be moderated"
• Quarterly combined ratio guidance — management refused to provide from Q3 FY2025 onward after being held to guidance that proved unachievable

What management started doing:

• Cohort-based and zone-based pricing (introduced FY2026) — first discussed at Q1 FY2026; represents a move from portfolio-level to granular risk segmentation
• "Normalized investment yield" (8%) as primary earnings metric — introduced Q4 FY2026 to strip MTM volatility from reported PAT
• IFRS-basis targets — FY2028 PAT of ₹2,500 Cr is now explicitly anchored to IFRS accounting

What stayed constant regardless of narrative rebranding:

• Agency channel dominance: 80%+ of GWP throughout; fresh agency +35% in 9M FY2026
• FY2028 PAT target: ₹2,500 Cr retained through every quarter, with only the accounting basis changed
• Super Star product emphasis: ₹550 Cr GWP at launch → ₹1,000+ Cr within 10 months

The narrative arc inside the narrative: The sequence — "growth with profit" (Q1 FY2025) → "year of change" (Q2 FY2025) → "risk first, growth later" (Q3 FY2025) → "year of the customer" (Q4 FY2025) — is four distinct framing resets across twelve months. The FY2026 reversal to actual results ("underwriting profit achieved") is the first quarter where the label matched the data.

---

3. Risk Evolution

Claims severity is the most important long-term risk. Post-COVID, management consistently cited "normalization" — until Q2 FY2025 revealed a 10% severity increase and 6% frequency increase that had not been modeled. The Q4 FY2026 loss ratio of 65.2% is genuinely improved, but the portfolio shift (exiting group business, repricing 65% of retail book) means the improvement is partly structural (portfolio cleaner) and partly cyclical (healthier quarter). Sustaining sub-67% loss ratios across multiple quarters will be the proof point.

Accounting discontinuities (1/N rule + IFRS transition) mean investors cannot meaningfully compare FY2026 performance to FY2024 without adjustment. Management introduced "normalized PBT" and IFRS underwriting profit as new metrics mid-cycle — useful transparency, but also creates discretion in what "comparable" means.

The cyber attack was disclosed in Q2 FY2025 and never followed up. No subsequent call mentioned remediation costs, regulatory action, or customer impact quantification. This is the single largest disclosure gap in the company's post-IPO history.

---

4. How They Handled Bad News

Star Health's bad-news communication pattern: initial minimization with data-selective framing → sequential narrative rebranding → structural action (much later). The FY2026 MTM disclosure is a meaningful improvement.

Pattern assessment: COVID losses received the "extraordinary event" framing that was broadly credible and accepted. FY2025 required four quarterly reframings and analyst confrontation before structural action followed. FY2026's MTM handling was comparatively honest and proactive. The direction of travel in disclosure quality is positive, but the company has not yet faced a crisis requiring disclosure before the issue was resolved — the cyber attack being the clearest example of the prior pattern.

---

5. Guidance Track Record

The FY2025 miss is what matters most. The company had a full year of guidance (beginning at Q1 FY2025, reaffirmed at Q2) that sub-100% combined ratio was achievable. The actual 101.1% — driven by a loss ratio 400bps above target — was not a single-quarter surprise. It accumulated across all four quarters. Management's loss ratio guidance was not a stretch target; it was presented as a base case anchored on the FHO repricing thesis. The thesis was partially wrong.

The FY2028 GWP target modification is material. "₹30,000 Cr may be moderated" (Q4 FY2025) followed by "focus shifted to PAT quality over GWP quantum" (Q1 FY2026) without a revised number is the pattern of retiring guidance by deprioritizing the metric — not by formally reducing the target.

The FY2028 PAT target retention with an accounting restatement (IGAAP → IFRS) warrants scrutiny. Management has not disclosed the IGAAP-to-IFRS PAT translation for prior years, making it impossible to confirm whether ₹2,500 Cr on IFRS is equivalent to, higher than, or lower than the original ₹2,500 Cr IGAAP target.

---

6. What the Story Is Now

Star Health enters FY2027 with three genuinely new conditions and two unresolved questions.

New condition 1 — Portfolio is cleaner than ever. Retail is 95%+ of GWP, fresh NTI mix is 94%, group employer-employee is fully exited, and 65% of the retail book has been repriced using cohort and zone-based methodologies. Q4 FY2026 loss ratio of 65.2% is the best quarter in the company's history, including the pre-COVID period.

New condition 2 — GST structural tailwind. The September 22, 2025 GST exemption on retail health insurance (18% → 0%) is the largest exogenous demand stimulus the category has seen. Management reported 50% fresh growth in October 2025. For a company that is 95% retail, this is a disproportionate benefit — but also creates a high FY2027 baseline and possible volume-without-discipline risk if growth is prioritized over underwriting.

New condition 3 — Accounting reset. IFRS transition and the 1/N accounting rule together make FY2026 effectively a new baseline. The company now reports underwriting profit/loss on IFRS terms (₹20 Cr for 9M FY2026 vs. −₹227 Cr prior year on the same basis). Comparisons to pre-FY2026 financials require adjustment that management has not yet formally provided.

Unresolved question 1 — Can the loss ratio hold? The improvement was partly structural (exiting group business, repricing retail) and partly portfolio-mix driven. Whether 65–67% loss ratio is sustainable across a full year — including monsoon quarters and as fresh business (which has a worse loss ratio than renewal) scales — is unknown.

Unresolved question 2 — Is the FY2028 PAT target real? Reaching ₹2,500 Cr PAT by FY2028 from FY2026's ₹911 Cr actual requires ~65% CAGR. Even from the ₹1,222 Cr normalized figure, the target needs ~43% CAGR across two years. Management's 80:20 investment/underwriting income split for the FY2028 target suggests investment income (₹840–₹875 Cr at current corpus) does roughly one-third of the work, with underwriting needing to contribute the rest. Achievable in a best-case scenario; not yet visible in the trajectory.